BridgeBio Pharma, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 17 rows in 2019. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2019-12-16: Reporting owner Cook Jennifer E.; Form 3; Security Stock Option (right to buy); Transaction Holding.
- 2019-12-12: Reporting owner SCHELLER RICHARD H; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2019-12-12: Reporting owner MOMTAZEE JAMES C; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2019-12-12: Reporting owner AGUIAR ERIC; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2019-12-16 holding as of filing | Cook Jennifer E. Director | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $31.14 exercise price | 2019-12-16 | ||
| 2019-12-12 | SCHELLER RICHARD H Director, Officer (See Remarks) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +82,878 82,878 owned after | $37.45 exercise price | $37.45 | 2019-12-16 |
| 2019-12-12 | MOMTAZEE JAMES C Director, 10% Owner | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +82,878 82,878 owned after | $37.45 exercise price | $37.45 | 2019-12-16 |
| 2019-12-12 | AGUIAR ERIC Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +82,878 82,878 owned after | $37.45 exercise price | $37.45 | 2019-12-16 |
| 2019-12-12 | HOMCY CHARLES J Director, Officer (Chairman of Pharmaceuticals) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +82,878 82,878 owned after | $37.45 exercise price | $37.45 | 2019-12-16 |
| 2019-12-12 | Cook Jennifer E. Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +82,878 82,878 owned after | $37.45 exercise price | $37.45 | 2019-12-16 |
| 2019-12-12 | Satvat Ali J. Director, 10% Owner | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +82,878 82,878 owned after | $37.45 exercise price | $37.45 | 2019-12-16 |
| 2019-11-13 | Stolz Brian M. Officer (Chief Operating Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +102,081 102,081 owned after | $26.28 exercise price | $26.28 | 2019-11-15 |
| 2019-11-13 | YAU YI CHING Officer (Chief Accounting Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +78,148 78,148 owned after | $26.28 exercise price | $26.28 | 2019-11-15 |
| 2019-06-27 holding as of filing | Turtle Cameron Officer (See Remarks) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $17.00 exercise price | 2019-06-27 | ||
| 2019-06-27 holding as of filing | SCHELLER RICHARD H Director, Officer (See Remarks) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $17.00 exercise price | 2019-06-27 | ||
| 2019-06-27 holding as of filing | Sinha Uma Officer (Chief Scientific Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $17.00 exercise price | 2019-06-27 | ||
| 2019-06-27 holding as of filing | STEPHENSON BRIAN C Officer (See Remarks) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $17.00 exercise price | 2019-06-27 | ||
| 2019-06-27 holding as of filing | HOMCY CHARLES J Director, Officer (Chairman of Pharmaceuticals) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $17.00 exercise price | 2019-06-27 | ||
| 2019-06-27 holding as of filing | HENDERSON MICHAEL THOMAS Officer (See Remarks) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $17.00 exercise price | 2019-06-27 | ||
| 2019-06-27 holding as of filing | Kumar Neil Director, Officer (See Remarks) | 3 | Stock Option (right to buy) Derivative · Direct · (m) | Holding | $17.00 exercise price | 2019-06-27 | ||
| 2019-06-27 holding as of filing | MCCORMICK FRANK Officer (Chairman of Oncology) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $17.00 exercise price | 2019-06-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |